D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $10.00 target price on the stock.
Several other research firms also recently weighed in on ANIX. Maxim Group initiated coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a "buy" rating and a $10.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, March 25th.
View Our Latest Analysis on Anixa Biosciences
Anixa Biosciences Trading Down 3.6 %
ANIX stock traded down $0.11 during midday trading on Wednesday, hitting $2.97. 81,233 shares of the company's stock were exchanged, compared to its average volume of 97,441. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The stock has a market capitalization of $95.63 million, a PE ratio of -7.62 and a beta of 0.86. The business has a 50-day simple moving average of $2.97 and a two-hundred day simple moving average of $3.00.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). As a group, research analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.
Insider Buying and Selling at Anixa Biosciences
In related news, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the completion of the transaction, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now owns 922,334 shares of the company's stock, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 75,289 shares of company stock valued at $177,021 in the last 90 days. Company insiders own 25.30% of the company's stock.
Hedge Funds Weigh In On Anixa Biosciences
Several large investors have recently bought and sold shares of the business. Millennium Management LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter valued at about $26,000. Focus Partners Wealth purchased a new position in Anixa Biosciences in the fourth quarter valued at approximately $162,000. Jane Street Group LLC acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $67,000. Renaissance Technologies LLC raised its holdings in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after purchasing an additional 3,900 shares in the last quarter. Finally, LPL Financial LLC lifted its position in shares of Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after buying an additional 11,633 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company's stock.
Anixa Biosciences Company Profile
(
Get Free Report)
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Further Reading
Before you consider Anixa Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anixa Biosciences wasn't on the list.
While Anixa Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.